Braveheart Bio has officially launched with a mission to transform cardiovascular medicine through advanced small-molecule therapies. The new biotech, led by CEO Travis Murdoch, is backed by leading investors including Forbion and OrbiMed, and debuts with a high-value licensing agreement with Jiangsu Hengrui Pharmaceuticals.

Under the deal, Braveheart Bio gains exclusive global rights, excluding China, Hong Kong, Macao and Taiwan, to develop, manufacture and commercialise the cardiac myosin inhibitor HRS-1893. The agreement includes an upfront payment of 65 million USD, split evenly between cash and shares, with additional potential milestones worth over 1 billion USD and royalties on future sales.

HRS-1893 is currently in Phase III trials in China for obstructive hypertrophic cardiomyopathy and has already shown strong early-phase data, suggesting best-in-class potential. With this asset, Braveheart Bio is positioning itself against major players in the field, including Bristol Myers Squibb’s Camzyos.

By combining global development rights with seasoned scientific leadership and strong investor backing, Braveheart Bio is establishing itself as a bold new contender in the cardiovascular therapeutics market.